| abstract |
It has a glucosylceramide lowering action (eg, glucosylceramide metabolism promoting action, glucosylceramide synthesis inhibiting action, glucosylceramide catabolic promoting action, etc.), and has lysosomal storage disease (eg, Gaucher's disease), neurodegenerative disease (eg, Parkinson's disease, Levy). Provided are compounds that are expected to be useful as prophylactic or therapeutic agents for small body dementia, multiple system atrophy) and the like. The present invention has the formula (I) :. [Each symbol in the formula is as described in the specification. ] With respect to a compound represented by or a salt thereof. |